Company profile
We build superior ADCs | Iksuda Therapeutics
Iksuda is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well as broader based therapeutics ...
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
RESOLUTIONS | Transaction WURFVk4zVkZhZGlxemtjeA | Paper/PDF filed
Published 19 Nov 2024 01:47
MA | Transaction MzQ0MTYzNDY3N2FkaXF6a2N4 | Paper/PDF filed
Published 19 Nov 2024 01:40
CS01 | Transaction MzQ0MTkxNDk1MGFkaXF6a2N4
Published 04 Nov 2024 04:00
AP01 | Transaction MzQ0MTY0MTYyN2FkaXF6a2N4
Published 31 Oct 2024 04:39
TM01 | Transaction MzQ0MTYzODI1NmFkaXF6a2N4
Published 31 Oct 2024 04:17
TM01 | Transaction MzQ0MTYzODIyNmFkaXF6a2N4
Published 31 Oct 2024 04:16
AP01 | Transaction MzQ0MTYzNzk2OGFkaXF6a2N4
Published 31 Oct 2024 04:14
AP01 | Transaction MzQ0MTYzNjgyM2FkaXF6a2N4
Published 31 Oct 2024 04:08
AA | Transaction MzQzNzAyMDU4MGFkaXF6a2N4 | Paper/PDF filed
Published 01 Oct 2024 06:16
TM01 | Transaction MzQzNDk3Mjc1NmFkaXF6a2N4
Published 10 Sep 2024 12:38
Company registered at Companies House
1 Feb 2017 to 30 Nov 2018
Antibody Drug Conjugates (ADCs) are an emerging class of targeted therapeutics with the potential to improve therapeutic index over traditional chemotherapy. By combining the targeting power of antibodies with the cell killing capability of potent cytotoxic molecules, it is possible to kill cancer cells more effectively whilst reducing debilitating side e...
1 Aug 2015 to 31 Jul 2016
Development of biotherapeutics is risky and expensive with current timelines from bench to bedside being estimated at 7-10 years at a cost of $2.8bn. This project exploits Glythera’s technology which can stabilise glycosylation profiles to increase bioavailability and the therapeutic window to enhance the efficacy of the drug but also patient care through...
